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Abstract We have designed two original sets of oligonucleotide
primers hybridizing the relatively conserved motifs within the
immunoglobulin signal sequences of each of the 15 heavy chain
and 18 kappa light chain gene families. Comparison of these
5P primers with the immunoglobulin signal sequences referenced
in the Kabat database suggests that these oligonucleotide primers
should hybridize with 89.4% of the 428 mouse heavy chain signal
sequences and with 91.8% of the 320 kappa light chain signal
sequences with no mismatch. Following PCR amplification using
the designed primers and direct sequencing of the amplified
products, we obtained full-length variable sequences belonging to
major (VH1, VH2, VH3, VU1 and VU21) but also small-sized
(VH9, VH14, VU2, VU9A/9B, VU12/13, VU23 and VU33/34) gene
families, from nine murine monoclonal antibodies. This strategy
could be a powerful tool for antibody sequence assessment
whatever the V gene family before humanization of mouse
monoclonal antibody or identification of paratope-derived
peptides.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Antibody molecules are unique because of their wide range
of binding speci¢cities coupled with many di¡erent e¡ector
functions. Hybridoma cells, mainly of rodent origin, are a
pure source of monoclonal antibody (mAb) of desired specif-
icity. The clinical potential of these mAbs is hindered because
therapeutic mouse antibodies can elicit an immune response in
humans. To overcome this problem, mouse/human chimeric
antibodies have been constructed by replacement of all but the
murine variable regions [1] or by grafting murine complemen-
tarity-determining regions (CDR) with human framework re-
gions (FR) [2]. Furthermore, bioactive paratope-derived pep-
tides (PDP) designed from mouse mAbs are also a powerful
tool to obtain minimal antibody-like structure [3,4] showing
the lowest human anti-mouse antibody response.
Such humanization of a mouse mAb or identi¢cation of
PDPs depends on e⁄cient ampli¢cation and sequencing of
murine variable regions from the mAb under investigation.
The polymerase chain reaction (PCR) is generally used with
5P primers which take advantage of conserved features of
framework [5^8] or signal (S) sequences [9^12] within anti-
body variable regions, in conjunction with a 3P oligonucleo-
tide probe directed to the constant region. A one-side PCR
using a 3P primer directed to the constant region has also been
described as being independent of the sequence of the variable
segment [13]. A strategy employing FR primers can lead to
the substitution of amino acids in the framework a¡ecting
antigen binding [14,15]. Of particular importance is the resi-
due at position 2 in FR1 of the light chain variable region,
which indirectly a¡ects the structure of CDR1 [16]. FR se-
quences can undergo somatic maturation leading to inad-
equate matching [17], whereas the frequency of possible point
mutations in the signal sequence is lower. Priming in the con-
served motifs from this immunoglobulin (Ig) signal region is
thus a possible powerful way to obtain entire sequences of
antibody variable regions. Various sets of signal sequence
primers have been described [9^12], but ampli¢cation of cer-
tain variable regions with these probes systematically fails,
mainly due to inadequate matching [12,18^20]. An extensive
analysis of the oligonucleotide sequences used [9^12] indicates
that they e⁄ciently match Ig signal regions from the major VH
gene families, i.e. VH1 (J558), VH2 (Q52), VH3 (36^60) or VH5
(7183), and from the major VU gene families, i.e. VU1, VU4/5,
VU19/28, VU21 or VU24/25, but they do not prime signal se-
quences from minor Ig gene families.
Murine V genes have been classi¢ed into 15 VH and 18 VU
gene families, based upon amino acid and/or nucleotide se-
quence similarities [21^25]. In an attempt to potentially am-
plify Ig genes from all V gene families, we have de¢ned two
original sets of leader primers which hybridize in the relatively
conserved signal sequences of each heavy and light chain gene
family. These primers have been routinely used in our labo-
ratory to amplify and directly sequence the full-length variable
regions from nine murine mAbs, including domains belonging
to seven di¡erent VU and ¢ve di¡erent VH gene families. Our
strategy allows rapid and accurate sequencing of variable re-
gions from any Ig gene family and should facilitate the design
of PDPs or chimeric antibodies of clinical interest.
2. Materials and methods
2.1. Mouse hybridoma cells
The following cell lines were used in the experiments: 27G7 (anti-
phosphonamidic hapten: IgG2b/U), 2C2 (anti-digoxin: IgG1/U [26]),
1C10 (anti-digoxin: IgG1/U [27]), Tg6 (anti-human thyroglobulin:
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IgG1/U [28]), 8G7B3 (anti-parvalbumin: IgG2a/U), 1F3 (anti-human
antithrombin III: IgG1/U), 11E12 (anti-human cardiac troponin I:
IgG2a/U [29]), ST40/F142.63 (anti-human CD4: IgG1/U [30]) and
13B8.2 (anti-human CD4: IgG1/U [31]). All the mAbs were produced
in our laboratory except mAb 13B8.2, which was kindly donated by
D. Olive and C. Mawas (INSERM U119, Marseille, France), and
mAbs ST40/F142.63 and 11E12, which were provided by D. Carrie're
and C. Larue, respectively (Sano¢ Recherche, Montpellier, France).
Hybridoma cells were obtained by fusing splenocytes with P3-
X63Ag8.653 myeloma cells except mAb 13B8.2, which was produced
by cell fusion of splenocytes with NS1 myeloma cells. Cells were
grown in RPMI 1640 medium with 10% fetal calf serum supplemented
with 2 mM glutamine, 100 Wg/ml streptomycin and 100 IU/ml pen-
icillin.
2.2. Primer design
Two databases of 491 mouse heavy chain and 356 mouse light
chain signal sequences, expanded from the Kabat database ([32],
http://immuno.bme.nwu.edu/), were used to design the PCR primers.
Each signal sequence was assigned to a VU or a VH gene family
[23,25], according to the related reference listed in the Kabat database.
The signal sequences belonging to the same Ig gene family were
aligned and the most conserved region was chosen to de¢ne consensus
signal sequence primers as depicted on Tables 1 and 2. The antisense
primer RevCUSalI (5P-CGACTAGTCGACTGGTGGGAAGATG-
GATACAG-3P) contains the reverse complement of codons 113^120
of kappa light chain constant region. The following antisense
oligonucleotides were designed to match the heavy chain constant
regions: RevCQ1SalI (5P-CGACAAGTCGACTAGCCCTTGACCA-
GGCATCC-3P ; matching codons 141^147 of CQ1), RevCQ2aSalI (5P-
CGACAAGTCGACTAACCCTTGACCAGGCATCC-3P ; matching
codons 141^147 of CQ2a), RevCQ2bSalI (5P-CGACTAGTCGAC-
CAGGGATCCAGAGTTCCAAG-3P ; matching codons 156^166 of
CQ2b) and RevCQ3SalI (5P-CGACTAGTCGACTAGCCTTTGA-
CAAGGCATCC-3P ; matching codons 141^147 of CQ3). These prim-
ers contained a SalI restriction site (underlined) for further cloning.
The 5P-CG-3P dinucleotide found in this restriction site is extremely
rare in mammalian genomes [33] and the frequency of SalI recogni-
tion sites in variable domains of mouse antibodies is approximately
0.1^0.2% [34].
2.3. cDNA synthesis and PCR ampli¢cation of VH and VU genes from
mouse hybridomas
Total RNA was extracted from 2U108 hybridoma cells using the
TRIzol technique (Gibco BRL, Grand Island, NY, USA) as described
by the manufacturer. 50 Wg of total RNA was annealed at 65‡C for
5 min with 10 pM of RevCUSalI primer for light chain cDNA syn-
thesis or appropriate RevCQSalI primer for heavy chain cDNA syn-
thesis in a 50 Wl ¢nal volume of 1U¢rst-strand cDNA synthesis bu¡er
(Gibco BRL) containing 10 WM dNTPs (Gibco BRL) and 1 mM DTT
(Gibco BRL). After annealing, the samples were cooled for 20 min at
20‡C. 400 U of reverse transcriptase Superscript II (Gibco BRL) and
40 U of RNase inhibitor (Promega, Madison, WI, USA) were then
added and the reaction was incubated for 1 h at 42‡C. Reverse tran-
scriptase activity was inactivated by incubation at 95‡C during 5 min
and cDNA was kept at 320‡C until use. PCR ampli¢cation was
carried out in a ¢nal volume of 20 Wl containing 1 Wl of cDNA syn-
thesis reaction, 10 WM dNTPs, 2 Wl of 10UPCR bu¡er (New England
Biolabs, Beverly, MA, USA). Fourteen VH and 18 VU PCR reactions
were set up using each group of family-speci¢c 5P primers (Tables 1
and 2) and the appropriate 3P-oligonucleotide probe matching the
light or heavy chain constant region. Two mixtures, containing all
VH or VU 5P primers, were also set up. No PCR reaction was per-
formed with primer speci¢c for the VH13 (3609N) gene family since
the only reported member assigned to this family is the non-functional
allele of PC3609 [35]. The amount of each primer used was initially
10 pM for non-degenerated oligonucleotide and was increased two- to
eight-fold depending on the degeneracy. The reaction mixtures were
heated to 94‡C for 10 min, then 2 U Vent DNA polymerase (New
England Biolabs) was added and 30 cycles of ampli¢cation were car-
ried out for 1 min at 94‡C, 1 min at 55‡C and 2 min at 72‡C. After a
10 min extension at 72‡C, the PCR products were fractionated
through a 1.5% agarose gel (Gibco) and stained with ethidium bro-
mide. Sets of 5P primers and 3P primers leading to a 390 bp product
for VU ampli¢cation and a 450 bp product for VH ampli¢cation were
selected from this family-speci¢c PCR screening. Five replicates using
the same selected primers were subjected to a new PCR as described
above. The PCR-ampli¢ed DNA products were gel puri¢ed on a
1.5%, low melting temperature agarose gel (Gibco).
2.4. Direct nucleotide sequencing of the ampli¢ed V genes
The gel-puri¢ed DNA products were directly sequenced on both
strands using the 3P and 5P primers selected above and the dideoxy
termination kit Thermo Sequenase (Amersham Pharmacia Biotech,
Cleveland, OH, USA), as described by the manufacturer except for
minor modi¢cations. Brie£y, the reaction mixture containing 100 ng
DNA ampli¢cation product, Thermo Sequenase DNA polymerase,
appropriate primer, [K-35S]dATP (ICN Pharmaceuticals, Costa
Mesa, CA, USA), dCTP, dGTP and dTTP was subjected to 50 label-
ing cycles of 15 s at 95‡C followed by 30 s at 50‡C. Then 3.5 Wl of the
labeling reaction was transferred onto each tube containing 4 Wl of
ddATP or ddCTP or ddGTP or ddTTP termination mix. The termi-
nation step corresponded to 30 cycles of PCR at 95‡C for 15 s, 55‡C
for 30 s and 72‡C for 1 min. The reaction was ended by addition of
4 Wl of stop solution. After electrophoresis, gel drying and ¢lm ex-
posure, 250^300 bases of V gene sequence were obtained for each
PCR product. Sequence comparison and germline gene analysis of
VH and VU regions used by the nine mAbs were performed using
the Kabat database [32].
3. Results
3.1. Evaluation of the 5P primers designed from heavy chain
signal sequences
Among the 491 VH signal sequences expanded from the
Kabat database under the item ‘mouse AND all.ig.heavy.-
chain.signal.sequence’, 64 sequences were eliminated by scan-
ning by eye because (1) they are assigned to another species or
(2) they show an incomplete nucleotide sequence (less than 12
bases annotated) or (3) only the amino acid sequence is avail-
able. The remaining 427 sequences were assigned to a VH gene
family as documented in the related references listed in the
Kabat database or in other related references. Furthermore,
one VH12-speci¢c signal sequence derived from GenBank was
added to our compilation since it was the only sequence re-
ported in both of these databases as corresponding to a signal
region from a VH12 hybridoma [36]. In this way, all the se-
lected signal sequences were classi¢ed among the 15 heavy
chain gene families, except for the VH13 (3609N) family show-
ing only one member reported as a non-functional rearrange-
ment [35]. These subgroups were divided according to amino
acid [21] and nucleotide [25,35,37^41] sequence similarity.
Alignment of all signal sequences inside each VH gene family
allowed the design of 32 non-degenerated or degenerated oli-
gonucleotides (Table 1). These heavy chain S primers (SH)
spanned positions 313 and 31 of the signal region.
Primer matching was evaluated by comparison of each de-
signed sequence with the 428 mouse heavy chain signal se-
quences. As shown in Table 1, 15 VH1 S primers were pre-
dicted to hybridize 200 signal sequences assigned to the major
VH1 gene family without any mismatch. Groups of two SH
primers were designed to potentially hybridize 34 signal se-
quences from the VH2 family, 28 from VH3, 22 from VH5 and
30 from VH7 with no mismatch. Other families were probed
with only one SH oligonucleotide, leading to 69 additional
sequences potentially ampli¢ed without any mismatch. Taken
together, our 32 selected 5P primers should be able to probe
379 heavy chain signal sequences without any mismatch, in-
dicating that 89.4% of the known murine heavy chain signal
sequences from the Kabat database exactly match with the set
of 5P-SH oligonucleotides we de¢ned. Finally, the facts that
(i) PCR tolerates primer/template DNA mismatches [42] and
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Fig. 1. Immunoglobulin heavy (VH) and kappa light (VU) chain PCR products derived from ¢rst-strand cDNA of four mouse mAbs. The am-
pli¢cation was performed as described in Section 2 with appropriate constant 3P primer and sets of signal 5P primers speci¢c for a given VH
(lanes 1^15) or VU (lanes 1^18) gene family. The 20 Wl PCR reaction was fractionated on a 1.5% agarose gel and the ampli¢cation products
were stained by ethidium bromide. (VH) The VH1^VH15 family-speci¢c sets of primers were used in lanes 1^15. (VU) Lane 1 shows the results
of ampli¢cation using the VU1 set of primers; lane 2, VU2 set of primers; lane 3, VU4/5; lane 4, VU8; lane 5, VU9A/9B; lane 6, VU10; lane 7,
VU11; lane 8, VU12/13; lane 9, VU19/28; lane 10, VU20; lane 11, VU21; lane 12, VU22; lane 13, VU23; lane 14, VU24/25; lane 15, VU32; lane
16, VU33/34; lane 17, VU31/38C; lane 18, VURF. In the mixture (mix), PCR products were obtained following ampli¢cation of cDNA with a
3P primer combined with all 5P signal oligonucleotides. M indicates the 100 bp ladder markers with the 400 bp marker annotated on the left.
Note that an inversion occurred for the VU ampli¢cation of mAb 27G7: lane 11 corresponds to ampli¢cation with the VU22 primer, whereas
lane 12 indicates ampli¢cation with the VU21 set of primers.
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(ii) 37 VH signal sequences were probed by the de¢ned oligo-
nucleotides with only one mismatch suggest that the true per-
centage of VH signal sequences potentially ampli¢ed is greater
than those estimated without mismatch.
3.2. Evaluation of the 5P primers designed from the kappa light
chain signal sequences
Three hundred and ¢fty-six VU signal sequences, expanded
from the Kabat database, were used to de¢ne the SU 5P-oli-
gonucleotides. An approach similar to the one described
above for SH primers led to the elimination of 36 unexploit-
able sequences. One signal sequence could not be clearly as-
signed to a VU gene family. As shown in Table 2, 31 consen-
sus SU 5P-oligonucleotides were de¢ned to probe the 319
remaining Ig signal sequences from the 18 described VU
gene families [22,24,43^45]. The designed oligonucleotide hy-
bridized between positions 315 and 31 of the signal region.
Sets of one to ¢ve primers are needed to match all the VU
gene families. Among the major light chain families, each
selected group of primers should potentially probe, with no
mismatch, 38 sequences from the VU1 family, 66 sequences
from the VU4/5 family, 21 from VU19/28, 23 from VU21 and
18 from VU24/25 (Table 2). A group of 154 additional sequen-
ces belonging to the 13 other VU gene families was further
predicted to be potentially matched by the remaining primers.
Taken together, 294 kappa light chain signal sequences, cor-
responding to 91.8% of the referenced VU signal sequences in
the Kabat database, could theoretically be primed by the se-
lected SU 5P-oligonucleotides with no mismatch. Probably
more than this calculated percentage of kappa light chain
signal sequences can be potentially ampli¢ed since the de-
signed SU primers hybridized 20 additional sequences with
only one mismatch.
3.3. PCR ampli¢cation of V genes from mouse hybridomas
using gene family-speci¢c signal primers
Fig. 1 shows the PCR ampli¢cation products for the VH
and VU chain regions of mAbs 27G7, 8G7B3, 1C10 and
13B8.2, using a combination of appropriate constant primer
and signal primers corresponding to a given VH (lanes 1^15)
or VU gene family (lanes 1^18). Similar experiments have been
successfully performed with ¢ve other mAbs (data not
shown). E⁄cient sets of primers should amplify a 450 bp
product for VH ampli¢cation and a 390 bp product for VU
ampli¢cation. From the cDNA of hybridoma cells secreting
the anti-phosphonamidic hapten mAb 27G7 (IgG2b/U), major
bands at the expected size were obtained with the VH2/Rev-
CQ2aSalI set of primers for heavy chain ampli¢cation and
with the VU21/RevCUSalI set of primers for VU ampli¢cation
(Fig. 1). In the same manner, VH3- and VU23-speci¢c primers
in combination with appropriate 3P primers led to major am-
pli¢cation products corresponding to the expected size for
variable regions of anti-parvalbumin mAb 8G7B3 (IgG2a/U).
A strong PCR ampli¢cation of the VH domain of the anti-
digoxin mAb 1C10 (IgG1/U) was obtained using the VH1 set
of primers in association with the RevCQ1SalI oligonucleotide,
whereas various sets of VU gene family-speci¢c sets of primers
(VU9A/9B, VU10, VU12/13) led to a strong 390 bp ampli¢ca-
tion product corresponding in size to the light chain variable
domain. Multiple hybridization was also observed for VH and
VU ampli¢cation of the variable regions from the anti-CD4
mAb 13B8.2. As shown in Fig. 1, a 13B8.2 DNA fragmentT
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with the size expected for a VH domain was obtained when
each of the di¡erent 5P primer groups (VH2, VH4, VH5 and
VH6) was used separately. Similarly, distinct VU family-specif-
ic oligonucleotides (VU9A/9B, VU10, VU12/13 and VU21) led
to a 390 bp fragment corresponding in size to a potential light
chain domain of 13B8.2 mAb.
Mixtures of all VH or VU primers associated with appropri-
ate constant primer-ampli¢ed PCR products at the expected
size for heavy or light chain variable domain, except for 27G7
VH ampli¢cation. DNA from antibodies of various isotypes
(IgG1, IgG2a and IgG2b) has been successfully ampli¢ed in-
dicating that the isotype speci¢city does not a¡ect the PCR
ampli¢cation.
3.4. Gene characterization of variable regions from nine mAbs
following direct sequencing of the ampli¢cation products
Further analysis of the assembled genes by direct sequenc-
ing of the ampli¢cation products (Table 3) showed that six of
the nine VH genes belong to major VH gene families (VH1,
VH2, VH3), whereas the three others are related to minor
families (VH9, VH14). Similarly, major (VU1, VU21) but also
small-sized (VU2, VU9A/9B, VU23 and VU33/34) gene families
are represented among the VU genes encoding the nine mAbs.
Inside each gene family, the closest germline genes have been
identi¢ed for all the variable regions sequenced, except for the
VU domain of the anti-troponin mAb 11E12. DH members
from the DSP2, DFL16 and DQ52 families in combination
with various JH genes were used for the VDJ rearrangement
of heavy chain variable regions. VJ rearrangement of variable
kappa light chain regions from the nine mAbs occurred by
using various JU gene segments. Full-length sequences of the
variable domains, as exempli¢ed by the deduced amino acid
sequence of the CDR3 region (Table 3), were characterized
for the nine mAbs under investigation. The sequences ob-
tained were identical to those previously described for the
anti-hapten mAb 27G7 (unpublished result) and for the
anti-CD4 mAb ST40 [4] by screening of a cDNA library.
Similarly, sequences of the anti-digoxin mAbs 2C2 and
1C10 were identical to those obtained using a PCR method
with FR primers [26,27]. The deduced N-terminal amino acid
sequence of the anti-troponin mAb 11E12 was also in accord-
ance with the sequence previously obtained following Edman
degradation of the heavy and light chain proteins (unpub-
lished data).
To try to explain the multiple hybridization we described
above for the DNA ampli¢cation of hybridomas 1C10 and
13B8.2, each PCR product obtained with distinct primers was
sequenced. DNA ampli¢cation using 5P primers VU9A/9B,
VU10 or VU12/13 for 1C10 light chain yielded the same
VU9A/9B-JU1 sequence (Table 3). Only one or two nucleotide
di¡erences were noted between certain S oligonucleotides
from each group of VU primers we de¢ned (Table 2). These
strong sequence homologies probably led to cross-matching of
these primers with the DNA template. From the 13B8.2 hy-
bridoma cells, the sequencing of the PCR product obtained
with VH2 primers yielded a full-length rearranged variable
heavy chain region as described in Table 3. In contrast, the
sequences resulting from PCR ampli¢cation with primers VH5
or VH6 contained a 50 bp deletion at the FR3-CDR3 boun-
dary, which led to a frameshift in the reading frame (data not
shown). This abnormal rearrangement corresponds to the P3
myeloma heavy chain pseudogene [46] found in the parental
NS1 cells used as the fusion partner. Ampli¢cation of light
chain cDNA from 13B8.2 hybridoma cells using 5P primers
VU9A/9B, VU10 or VU12/13 yielded an identical sequence
completely rearranged as described in Table 3, whereas the
VU PCR product ampli¢ed with VU21 primers corresponds
to a non-functionally rearranged kappa light chain (data not
shown) transcribed in myeloma cell lines, like NS1, derived
from the original MOPC21 tumor [47].
4. Discussion
In this study, we designed and demonstrated the usefulness
of two original sets of consensus signal primers for the am-
pli¢cation and subsequent direct sequencing of mouse VH and
VU regions from any V gene family. This strategy can lead to
easier and faster humanization of mouse mAb [1] or identi¢-
cation of paratope-derived peptides [3,4]. Although various
sets of primers have yet to be described [9^12], 15^35% of V
gene ampli¢cation fails [48], mainly due to inadequate match-
ing within selected PCR primers. This strong mismatch is
probably due to an inappropriate choice of oligonucleotides
for ampli¢cation of certain V gene families. Particularly, the
designed primers [9^12] e⁄ciently probe immunoglobulin sig-
nal sequences from major VH or VU families showing numer-
ous germline genes but cannot amplify V regions from minor
families having a small number of germline genes. For exam-
ple, major VH gene families, i.e. VH1, VH2 and VH3, represent
40^60% [49], 10^30% and 7%, respectively, of all heavy chain
variable regions expressed [50]. Since adult variable region
expression is proportional to the number of genes in a given
V gene family [51], if one designs primers which only hybrid-
ize signal sequences from these major VH families, a large
majority of the murine variable heavy chains can potentially
be ampli¢ed but VH genes from small-sized families would fail
to be obtained.
During the last 10 years, many signal sequences from im-
munoglobulin variable regions have become available leading
to an enriched and more accurate database [32]. Since V genes
have been classi¢ed into 15 VH and 18 VU families depending
on amino acid and/or nucleotide similarities [23,25], we can
assume that grouping signal sequences according to this clas-
si¢cation can lead to the design of primers representative of
all the gene families. We deliberately chose to design a wide
range of PCR primers with no or limited degeneracy and to
adapt the primer concentration according to this degeneracy.
In this way, a similar e⁄cient concentration for each primer
was maintained and thus the chances of amplifying certain
variable regions were not diminished. Using our sets of signal
primers, we have been able to obtain the complete V region
sequences belonging to major (e.g. VH1 or VU21) but also
minor gene families (e.g. VH14 or VU23), from nine mAbs
of di¡erent isotypes. These antibodies showed di¡erent anti-
genic speci¢cities ; notably they recognized a wide range of
molecules from hapten to large protein. The deduced full-
length amino acid sequence of each mAb is available, and
thus any residue alteration that could in£uence CDR confor-
mation and hence antigen binding was avoided [14^16]. Fur-
thermore, the dissection of V gene ampli¢cations for a given
hybridoma by using multiple family-speci¢c sets of signal pri-
mers allows the discrimination between the productive VDJ or
VJ rearrangement and aberrant transcripts. By direct sequenc-
ing of PCR products, we were able to rapidly identify pseu-
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dogenes belonging to the fusion partner [46,47], described by
us and others as contaminating the PCR ampli¢cation results
[52^54], and non-productive rearrangement with a reading
frameshift, as exempli¢ed by the 11E12 mAb (unpublished
data). With regard to our PCR strategy, other successful
methods such as anchored PCR [55] or inverted PCR [54]
are more time consuming, require extra steps, demand the
synthesis of large PCR products, which may be di⁄cult to
sequence directly and lead to reduced cloning e⁄ciency.
Our approach makes it possible to e⁄ciently amplify and
directly sequence in less than 2 weeks full-length immunoglo-
bulin variable domains whatever the V gene family. These
family-speci¢c signal primers should be helpful in studying
V gene selection in B-cell development or in various B cell
disorders and in characterizing hybridomas for further chim-
erization. In addition, the ampli¢ed V genes could easily be
inserted into our baculovirus expression cassettes for the pro-
duction of either the entire immunoglobulin molecule or only
the Fab fragment [56] or for the production of single chain Fv
[27].
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